ImmunoMet Therapeutics, a clinical stage biotechnology company targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies, today announced that it has been accepted to present a clinical study poster at the American Society of Clinical Oncology (ASCO) Virtual Scientific Program to be held Friday, May 29, 2020 through Sunday, May 31, 2020.

The poster, titled “Phase 1 study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors”, will provide a summary of findings from the company’s recently completed clinical study.  The study’s objectives were primarily to determine maximum tolerated dose / recommended
Phase 2 dose and to assess dose limiting toxicities.  Secondary objectives were to determine safety and tolerability, pharmacokinetics, and preliminary antitumor activity of IM156.

“We are pleased to be able to share the results of our Phase 1 study for our lead molecule, IM156, at ASCO. IM156 is the first potent Protein Complex 1 inhibitor to complete Phase 1 study with good tolerability” said Benjamin Cowen, PhD, MBA, ImmunoMet President and CEO.

IM156, a novel potent oral biguanide, is a protein complex 1 (PC1) inhibitor that targets the OXPHOS pathway in mitochondria.  Preclinical experiments demonstrated that IM156 can be effective in gastric cancer, lung cancer and other solid tumors. In a recently completed Phase 1 study, IM156 was well-tolerated in solid tumors patients. IM156 also blocks metabolic reprogramming in fibroblasts and preclinical studies has been shown to be effective in lung, peritoneal, liver and kidney fibrosis models.

About ImmunoMet Therapeutics
ImmunoMet is a clinical stage biotech targeting cellular metabolism to develop novel anti-tumor and anti-fibrotic therapies. Our lead molecule, IM156, is a protein complex 1 (PC1) inhibitor which demonstrated impressive in-vivo efficacy in resistant solid tumors. IM156 is the first potent PC1 inhibitor to complete Phase 1 with a good safety profile. The company was founded in 2015, is headquartered in the Houston JLABS@TMC near MD Anderson, and has raised $24M to date. For more information about the company, please visit www.immunomet.com.

Company Contact:
Benjamin Cowen, PhD, MBA
President and CEO of ImmunoMet
bcowen@immunomet.com